Sharon Kozachik, PhD, RN, FAAN, discusses the correlation between sleep and pain.
Palliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.
The R25 Nursing Grant program challenges oncology nurses to rethink how to care for older patients with cancer.
Frequent communication between patients and providers is key in getting ahead of adverse events that can occur during breast cancer treatment, explained Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.
Nina Kadan-Lottick, MD, associate professor of Pediatrics (Hematology/Oncology and medical director of the HEROES program at Yale School of Medicine, discusses ways to improve survivorship care plans.
Nurses play a key role in treating patients with myeloma.
Eva Pendleton, LMT, manager, integrative health, Perlmutter Cancer Center at NYU Langone, discusses the evidence supporting the use of integrative therapies during a patient's cancer treatment.
Brianna Hoffner, MSN, RN, ANP-BC, AOCNP, nurse practitioner, The Angeles Clinic and Research Institute, discusses how to monitor the adverse events in patients receiving treatment for melanoma.
The management of patients with colorectal liver metastases is complicated and requires careful assessment from a multidisciplinary tumor board—especially in light of recent advances made with chemotherapy, according to Michael J. Cavnar, MD.
In just over 5 years, the growth and development in the field of breast cancer have been astronomical. Julie Nangia, MD, Assistant Professor of Medicine, Baylor College of Medicine, discusses the recent explosion of knowledge about non-BRCA genes, and the significant progress in therapies targeted to BRCA mutation carriers.
Following a high rate of CDIs, the inpatient medical oncology unit at the University of California, Los Angeles, Santa Monica Medical Center adapted an evidence-based intervention.
Jenna Forsythe, MSN, RN, OCN, a nurse in the leukemia and lymphoma outpatient center at John Theurer Cancer Center, discusses some of the challenges patients with leukemia and lymphoma face.
Rowan Chlebowski, MD, PhD, Professor and Chief, Harbor-UCLA Medical Center, Department of Internal Medicine, Medical Oncology/Hematology Member, Jonsson Comprehensive Cancer Center, discusses the results of the Women's Intervention Nutrition Study (WINS).
Melissa Andres explains the role of the nurse navigator for patients with cancer.
Suzanne Walker, CRNP, MSN, AOCN, BC, University of Pennsylvania Health System, discusses a study looking at enhancing the end-of-life transition with FaceTime.
Women diagnosed with early-stage breast disease have a variety of decisions to make regarding their treatment options. For example, some women may be eligible for breast-conserving surgery, which typically includes a lumpectomy followed by radiation.
Gail Moore, BSN, RN, OCN, discusses the warning signs of cardiotoxicity from chemotherapy that nurses and patients should be aware of.
Maureen E. Thyne, RPA-C, Weill Cornell Medical College, discusses the impact that ruxolitinib (Jakafi) has had on patients with myelofibrosis.
Tricia Strusowski, MS, RN, Oncology Solutions, discusses the importance of the nurse navigator role, especially in community oncology settings, at the 2017 ACCC Cancerscape meeting.
Nurse navigators should consider sustainability strategies to ensure that their progress remains.
Kevin Oeffinger, MD, Director of the Cancer Survivorship Center at Memorial Sloan Kettering Cancer Center, discusses the importance of cancer survivorship in the primary care setting.
Areej El-Jawahri, MD, an oncologist at Massachusetts General Hospital, discusses how patients with cancer do not often have a full understanding of the terms and processes doctors describe during treatment.
As those of us immersed in our roles as oncology nurse navigators know only too well, each day holds the potential to be filled with unexpected
Regina Cunningham discusses her path from oncology nurse to hospital system CEO and shares insights on how nurses can leverage their unique skills to assume leadership roles.
The FDA accepted a resubmission of a new drug application for frontline rivoceranib plus camrelizumab to treat unresectable, metastatic HCC.